2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/
2020-12-14
Camurus announced on December 10, 2020, that the ICC International Court of Arbitration has issued a partial award i…
Read more2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US…
Read more2020-12-02
GAIM launches their new website on the domain www.gaim.com
Read more2020-11-06
"Good performances were seen across markets and we are on track to deliver on our revenue guidance."
Read more2020-07-29
ISEC Monitoring Systems has received three substantial and strategically important orders during the last year, amou…
Read more